16+
Major trials tracked
Immuno-oncology checkpoint inhibitors · Live ClinicalTrials.gov data
Pembrolizumab (Keytruda) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 pembrolizumab trials on ClinicalTrials.gov by enrolment, 5 of them actively recruiting. The next phase 3 primary completion among them is expected Jan 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.
8
Phase 3 trials
5
Actively recruiting
Jan 2027
Next phase 3 primary completion
7,047
Participants across trials
Merck Sharp & Dohme LLC
Lead sponsor by trial count
pembrolizumab (16)13 active2013–2033
pembrolizumab
'13
'15
'17
'19
'21
'23
'25
'27
'29
'31
'33
pembrolizumab
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)P2
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.P2
KEYNOTE-966P3
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung CancerP2
AcceleRET-LungP3
AxiPROP3
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)P2
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaP2
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2P3
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaP3
SUNRAY-01P3
STELLAR-305P2
LUNAR-2P3
Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal CancerP2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)P2
KRASCENDO 3P3
Upcoming readouts
9 ahead · pembrolizumab
Select a trial to load its full ClinicalTrials.gov record.
Key pembrolizumab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06119581 | SUNRAY-01 — A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With A… | Phase 3 | Recruiting | Nov 2027 |
| NCT06216301 | LUNAR-2 — LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | Recruiting | Oct 2028 |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Phase 3 | Active, not recruiting | Jan 2027 |
| NCT07541170 | KRASCENDO 3 — A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy … | Phase 3 | Not yet recruiting | Jan 2032 |
| NCT04003636 | KEYNOTE-966 — Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Ad… | Phase 3 | Completed | Dec 2022 |
| NCT04764487 | AxiPRO — A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanc… | Phase 3 | Unknown | Jun 2023 |
| NCT06320353 | Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic S… | Phase 3 | Unknown | Jun 2024 |
| NCT04222972 | AcceleRET-Lung — A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer… | Phase 3 | Terminated | Jan 2025 |
| NCT04093167 | Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | Phase 2 | Recruiting | Dec 2026 |
| NCT06698757 | Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instabilit… | Phase 2 | Recruiting | Nov 2027 |
| NCT06780085 | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell … | Phase 2 | Recruiting | Mar 2032 |
| NCT05805501 | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advan… | Phase 2 | Active, not recruiting | Oct 2026 |
Related drug pipelines
FAQ
- How many clinical trials are running for pembrolizumab?
- ClinicalTrials.gov lists more than 16 phase 2–4 pembrolizumab trials. This page tracks the 16 largest by enrolment: 8 phase 2, 8 phase 3, and 0 phase 4 among them, with 5 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare pembrolizumab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.